Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MGA271: Phase I started

MacroGenics began the dose-expansion portion of an open-label, U.S. Phase I trial to evaluate 15 mg/kg IV MGA271 given for the first 3 weeks of a 4-week

Read the full 270 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE